NCT05921734Completed
A Randomized Controlled Study of Ablation Pursuing Atrial Fibrillation Termination as a Procedural Endpoint in Patients With Persistent Atrial Fibrillation
A Randomized Controlled Study of Ablation Pursuing Atrial Fibrillation Termination as a Procedural Endpoint Versus Prespecified Ablation Strategy Followed by Cardioversion in Patients With Persistent Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 12 Sept 2025
Brief summary (registry, in English)
This is a prospective, randomized, multi-center trial that aims to investigate whether termination of atrial fibrillation can be used as an ablation endpoint for persistent atrial fibrillation (PersAF). Eligible patients who provided consent were randomly assigned to one of two groups: the AF-termination group (whose ablation endpoint was the pursuit of AF-termination) or the prespecified-ablation group (whose ablation endpoint was prespecified ablation followed by electrical cardioversion).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 480 (actual)
- First submitted
- 10 Jun 2023
- Start date
- 1 Aug 2023
- Primary completion date
- 1 Aug 2024
- Lead sponsor
- Shanghai Chest Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT05921734
What you commit to
- Study type: Interventional
- Participants enrolled: 480
- From 1 Aug 2023 to the primary completion date, 1 Aug 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- . The use of anticoagulant drugs is contraindicated;
- . Prior left atrial ablation (surgical or catheter);
Other illness
- . Uncontrolled congestive heart failure;
- . History of severe valve disease and/or prosthetic valve replacement;
- . Myocardial infarction or stroke within 6 months;
- . Severe congenital heart disease;
- . Contrast agent allergy;
- . Severe lung disease;
- . Contraindications for cardiac catheterization;
- . Have performed any cardiac surgery within 2 months;
Other
- . EF \<35%;
- . Left atrial thrombus confirmed by preoperative esophageal ultrasound;
- . Poor general health;
- . Life expectancy \< 12 months.
Who the study is looking for
- . Age 18-80 years old.
- . Patients undergoing a first-time ablation procedure for PersAF.
- . Diagnosed as persistent AF according to the latest clinical guidelines.
- . Ineffective or intolerable to ≥1 anti-arrhythmia drug treatment.
- . Patients must be able and willing to provide written informed consent to participate in this study.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Chest Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Mu Qin Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.